From the ∗Tulane University School of Medicine
†Deming Department of Medicine
‡Department of Radiology, Tulane University School of Medicine
§Tulane Cancer Center, New Orleans, LA.
Received for publication July 29, 2022; revision accepted October 22, 2022.
Conflicts of interest and sources of funding: A.O.S. is consultant to Advanced Accelerator Applications (AAA), Astellas, AstraZeneca, Bayer, Blue Earth Diagnostics Inc, Bavarian Nordic, Bristol Myers Squibb, Clarity Pharmaceuticals, Clovis, Constellation, Dendreon, EMD Serono, Fusion, Isotopen Technologien Meunchen, Janssen, Myovant, Myriad, Noria Therapeutics Inc, Novartis, Noxopharm, Progenics, POINT Biopharma, Pfizer, Sanofi, Tenebio, Telix, and Theragnostics. The other authors have none declared. Grant or research support was provided by Advanced Accelerator Applications, Amgen, AstraZeneca, Bayer, Constellation, Endocyte, Invitae, Janssen, Lantheus, Merck, Progenics, and Tenebio.
Correspondence to: Sydney A. Caputo, BS, 1430 Tulane Ave, Box 8642, New Orleans, LA 70112. E-mail: [email protected].
